AbCellera Biologics Inc. (ABCL)
$
5.59
-0.25 (-4.47%)
Key metrics
Financial statements
Free cash flow per share
-0.4656
Market cap
1.7 Billion
Price to sales ratio
50.8114
Debt to equity
0.1411
Current ratio
11.0730
Income quality
0.4880
Average inventory
0
ROE
-0.1591
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
AbCellera Biologics Inc. is at the forefront of developing an innovative antibody discovery platform powered by artificial intelligence. The financial data pertains to the fiscal year 2024 offering insight into the company's operational health. With an EBITDA ratio of -7.08 the company demonstrates its operational efficiency. AbCellera also earned an interest income of $38,473,000.00 showcasing its capacity for financial investments. The income before tax ratio stands at -6.95 reflecting the pre-tax margin, while the net income ratio of -5.65 highlights the company's profitability margin. As of December 31, 2021, AbCellera had initiated 156 discovery programs, either completed, in progress, or under contract with 36 partners, including a notable research collaboration and license agreement with Eli Lilly and Company. Since its incorporation in 2012, the company has established its headquarters in Vancouver, Canada, strengthening its position in the biotechnology sector. This company operates within the biotechnology industry, characterized by its cutting-edge solutions and significant contributions to the overall market landscape. The stock is affordable at $4.51 making it suitable for budget-conscious investors. Furthermore, the stock has a high average trading volume of 5,583,595.00 indicating strong liquidity, which can be appealing for investors looking for manageable entry points. With a market capitalization of $1,670,475,984.00 AbCellera is classified as a small-cap player. It belongs to the Healthcare sector, driving innovation and growth within its domain. These attributes make AbCellera a key player in the industry, reflecting its potential for future expansion and investor interest.
Is AbCellera Biologics Inc. (ABCL) a good investment?
Investing in AbCellera Biologics Inc. (ABCL) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is AbCellera Biologics Inc. (ABCL)'s stock forecast?
Analysts predict AbCellera Biologics Inc. stock to fluctuate between $1.89 (low) and $6.52 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is AbCellera Biologics Inc.'s market capitalization?
As of 2025-10-17, AbCellera Biologics Inc.'s market cap is $1,670,475,984, based on 298,832,913 outstanding shares.
How does AbCellera Biologics Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, AbCellera Biologics Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy AbCellera Biologics Inc. (ABCL) stock?
To buy AbCellera Biologics Inc. (ABCL) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABCL. Place an order (Market, Limit, etc.).
What is the best time to invest in AbCellera Biologics Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did AbCellera Biologics Inc. perform in the last earnings report?
Revenue: $28,833,000 | EPS: -$0.55 | Growth: 7.84%.
Where can I find AbCellera Biologics Inc.'s investor relations reports?
Visit https://www.abcellera.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for AbCellera Biologics Inc.?
You can explore historical data from here
What is the all-time high and low for AbCellera Biologics Inc. stock?
All-time high: $22.63 (2021-09-17) | All-time low: $1.89 (2025-04-07).
What are the key trends affecting AbCellera Biologics Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivot from a service provider to a proprietary drug developer targets high-growth monoclonal antibody markets, with promising candidates ABCL635 and ABCL575 entering clinical trials. Despite recent revenue and net income declines due to the business model shift, ABCL is well-funded and expects revenue to double in 2026 as clinical batches commence.
zacks.com
Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.
businesswire.com
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer.
seekingalpha.com
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chairperson Tryn T.
zacks.com
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.13 per share a year ago.
zacks.com
ABCELLERA BIOLG (ABCL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
zacks.com
ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
fool.com
Investors were surely discovering drug discovery company AbCellera Biologics (ABCL 6.19%) as the trading week kicked off on Monday. On encouraging news in an important North American jurisdiction, those folks bid the biotech's stock up by almost 6% on the day.
businesswire.com
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575.
businesswire.com
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause.
See all news
